AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca is currently recruiting for a clinical study titled ‘A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Relapsed or Refractory Multiple Myeloma’. The study aims to assess the safety and efficacy of AZD0305, a new drug for patients with relapsed or refractory multiple myeloma, who have undergone at least three prior treatments.
The study is testing AZD0305, an experimental drug, both as a standalone treatment and in combination with other anticancer agents. The goal is to determine its safety and effectiveness in treating multiple myeloma.
This interventional study follows a sequential model with no masking, focusing on treatment. It includes dose escalation and expansion phases to optimize dosing strategies.
The study began on December 5, 2023, with the last update submitted on August 13, 2025. These dates are crucial as they mark the study’s progress and regulatory updates.
The outcome of this study could significantly influence AstraZeneca’s stock performance and investor sentiment, especially if AZD0305 proves effective. This development is particularly relevant in the competitive oncology market.
The study is ongoing, with further details available on the ClinicalTrials portal.